Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc. (T:BHC)

Business Focus: Pharmaceuticals

INK Edge Outlook

This company is also listed in the United States as BHC on the NYSE. Click here to get the live US quote and see if there are any SEC insider filings..

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BHC within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 11, 2020 07:00 ET
Health Canada Issues Notice of Compliance for Bausch Health's DUOBRII™
TOPICAL COMBINATION IMPROVING THE SIGNS AND SYMPTOMS OF PLAQUE PSORIASIS IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FORMULATED WITH PROPRIETARY PRISMATREX™ TECHNOLOGY i
Read full article
Dec 19, 2019 15:01 ET
Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program
LAVAL, QC, Dec. 19, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced that VYZULTA® (latanoprostene bunod ophthalmic solution, 0.024%), which is indicated  for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, will be  listed as a limited use product under the Ontario Drug Benefit (ODB) Formulary.ii The product will be added to formulary on Dec. 20, 2019. 
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.22
--
--
Price to Sales - TTM
0.78
4.90
8.64
Price to Book - most recent quarter
9.37
2.30
2.51
Price to Cash Flow per share - TTM
49.20
8.97
11.85
Price to Free Cash Flow per share - TTM
6.44
12.84
22.34
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 20202,375,385-166,647
Jun 15, 20202,542,032-1,880
May 31, 20202,543,91291,806
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

See business summary

 

Twitter

Search (past week) for $BHC.CA